Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LIVN 
LivaNova PLC (LIVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: LIVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $61.03
1 Year Target Price $61.03
| 4 | Strong Buy |
| 4 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.74% | Avg. Invested days 53 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.42B USD | Price to earnings Ratio - | 1Y Target Price 61.03 |
Price to earnings Ratio - | 1Y Target Price 61.03 | ||
Volume (30-day avg) 11 | Beta 0.91 | 52 Weeks Range 32.48 - 57.35 | Updated Date 07/12/2025 |
52 Weeks Range 32.48 - 57.35 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.07 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -17.42% | Operating Margin (TTM) 15.54% |
Management Effectiveness
Return on Assets (TTM) 4.55% | Return on Equity (TTM) -19.7% |
Valuation
Trailing PE - | Forward PE 22.27 | Enterprise Value 2356537882 | Price to Sales(TTM) 1.9 |
Enterprise Value 2356537882 | Price to Sales(TTM) 1.9 | ||
Enterprise Value to Revenue 1.85 | Enterprise Value to EBITDA 327.96 | Shares Outstanding 54525700 | Shares Floating 54335396 |
Shares Outstanding 54525700 | Shares Floating 54335396 | ||
Percent Insiders 0.38 | Percent Institutions 102.95 |
Upturn AI SWOT
LivaNova PLC
Company Overview
History and Background
LivaNova PLC was formed in 2015 through the merger of Sorin S.p.A. and Cyberonics, Inc. Sorin was founded in 1956 focusing on cardiovascular devices, while Cyberonics was founded in 1987, specializing in neuromodulation therapies.
Core Business Areas
- Cardiovascular: Develops and manufactures devices for cardiac surgery and structural heart procedures, including heart-lung machines, oxygenators, and tissue valves.
- Neuromodulation: Focuses on therapies for neurological diseases, primarily using vagus nerve stimulation (VNS) for treatment-resistant epilepsy and depression.
Leadership and Structure
The current CEO is William Kozy. The company operates with a global structure, organized around its two main business units: Cardiovascular and Neuromodulation. Their headquarters are in London, UK.
Top Products and Market Share
Key Offerings
- CardioCel: A regenerative tissue patch used in cardiovascular repair and reconstruction. Market share is estimated at around 5-10% within the surgical patch market. Competitors include Baxter (BAX), LeMaitre Vascular (LMAT), and Getinge (GETI_B.ST).
- VNS Therapy System (for Epilepsy): A vagus nerve stimulation device used to reduce the frequency of seizures in patients with drug-resistant epilepsy. LivaNova holds a significant market share (estimated 50-60%) in the VNS therapy market. Competitors include Medtronic (MDT) and Boston Scientific (BSX), which are developing competitive neuromodulation devices.
- LifeSpan: A heart-lung machine. Market share data unavailable. Competitors include Medtronic (MDT) and Getinge (GETI_B.ST).
Market Dynamics
Industry Overview
The medical device industry is experiencing growth driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. The neuromodulation market is also growing due to increasing acceptance of these therapies and expanding applications.
Positioning
LivaNova holds a strong position in the VNS therapy market and a competitive position in select cardiovascular device segments. Its competitive advantage lies in its established VNS technology and specialized cardiovascular products.
Total Addressable Market (TAM)
The cardiovascular and neuromodulation markets are estimated to be worth billions of dollars annually. LivaNova is positioned to capture a portion of these markets through its existing product portfolio and pipeline of new products. The Cardiovascular TAM is estimated at $18B, and Neuromodulation at $8B. LivaNova holds a relatively smaller position in both these TAMs.
Upturn SWOT Analysis
Strengths
- Established VNS technology
- Specialized cardiovascular products
- Global presence
- Strong brand recognition in specific niches
Weaknesses
- Reliance on VNS therapy for revenue
- Limited product diversification
- Relatively small size compared to major competitors
- Past Legal liabilities
Opportunities
- Expanding applications of neuromodulation
- Developing new cardiovascular devices
- Entering emerging markets
- Strategic acquisitions and partnerships
Threats
- Increasing competition from larger medical device companies
- Regulatory changes and healthcare reforms
- Product liability claims
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Boston Scientific (BSX)
- Getinge (GETI_B.ST)
- Baxter (BAX)
Competitive Landscape
LivaNova faces stiff competition from larger, more diversified medical device companies like Medtronic and Boston Scientific. While LivaNova has a strong position in VNS therapy, its overall market share is smaller compared to these giants.
Major Acquisitions
Imthera Medical
- Year: 2019
- Acquisition Price (USD millions): 225
- Strategic Rationale: Expanded LivaNova's portfolio into obstructive sleep apnea (OSA) treatment with the Aura6000 device.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been mixed, with periods of strong growth in neuromodulation offset by challenges in the cardiovascular business.
Future Projections: Future growth is expected to be driven by new product launches in both cardiovascular and neuromodulation, as well as geographic expansion. Analyst estimates vary, but suggest moderate growth in revenue and earnings.
Recent Initiatives: Recent initiatives include the development of new VNS therapy applications, strategic partnerships to expand market access, and cost reduction programs.
Summary
LivaNova has a leading position in neuromodulation via VNS but faces challenges from larger competitors in the cardiovascular market. VNS provides a stable revenue base but growth depends on new applications and geographic expansion. Strategic acquisitions and cost controls are important for future profitability. They must also monitor and adapt to ongoing regulatory changes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LivaNova PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1993-02-10 | CEO & Director Mr. Vladimir A. Makatsaria | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2900 | Website https://www.livanova.com |
Full time employees 2900 | Website https://www.livanova.com | ||
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.